淋巴瘤

预约门诊

淋巴瘤分期

如果确诊淋巴瘤，下一步是确定癌症的扩散范围（称为分期）。影像学检查、血液检测和活检可能用于确定淋巴瘤的分期。医护团队使用癌症分期来帮助制定治疗计划。

淋巴瘤的分期可能会因具体类型不同而略有差异。总体而言，淋巴瘤的分期从 1 期到 4 期不等：

  • 淋巴瘤 1 期。 淋巴瘤 1 期仅累及一个淋巴结区域或淋巴结外的一个部位。
  • 淋巴瘤 2 期。 淋巴瘤 2 期累及膈膜同侧的两个或多个淋巴结区域。
  • 淋巴瘤 3 期。 淋巴瘤 3 期累及膈膜两侧的淋巴结区域。
  • 淋巴瘤 4 期。 淋巴瘤 4 期累及淋巴结以外的区域。

淋巴瘤预后

癌症预后能告知您癌症可被治疗或治愈的可能性。您的预后可能取决于：

  • 您的年龄。
  • 整体健康状况。
  • 您所患淋巴瘤的类型。
  • 癌症分期。
  • 您的血液检测结果。

如果您想了解预后情况，请咨询医护团队。医护团队成员可以阐明在评估您的预后时会考虑哪些因素。

申请预约
诊断与治疗生存率
Jan. 13, 2026

Living with 淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

amyboylan1
Is there anything to help stop or slow progression of MGUS?

157 Replies Wed, Feb 04, 2026

sandramgus
Diagnosed: MGUS

150 Replies Wed, Feb 04, 2026

See more discussions
  1. Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq. Accessed Aug. 6, 2025.
  2. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Aug. 6, 2025.
  3. Primary CNS lymphoma treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq. Accessed Aug. 6, 2025.
  4. Mycosis fungoides (including Sezary Syndrome) treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq. Accessed Aug. 6, 2025.
  5. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Aug. 6, 2025.
  6. Cancer stat facts: Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/hodg.html. Accessed Aug. 6, 2025.
  7. Elsevier Point of Care. Clinical Overview: Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  8. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  9. Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  10. Larson RA, et al. Tumor lysis syndrome: Prevention and treatment. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025.
  11. Elsevier Point of Care. Clinical Overview: Febrile neutropenia in adults. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  12. Robetorye R, et al. Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx Testing) into the routine work-up of diffuse large B-cell lymphoma. Journal of Hematopathology. 2019; doi:10.1007/s12308-019-00344-0.
  13. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  14. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Aug. 6, 2025.
  15. Membership institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Aug. 6, 2025.

相关

相关医疗程序

产品与服务

淋巴瘤

CON-20304579